SCHEMBL2799217

SCHEMBL2799217

CNC(=O)c1cc(=O)n(CCN2CCC(N(C)c3sc4scc(C)c4c3C)CC2)c2cc(OC)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.39
CNR1 P21554 3/20 0.34
CNR2 P34972 3/20 0.34
OPRM1 P35372 3/20 0.33
OPRL1 P41146 3/20 0.33
OPRD1 P41143 1/20 0.33
ALDH1A1 P00352 2/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
RECQL P46063 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CCNE2 O96020 2/20 0.31
CDK4 P11802 2/20 0.31
PRKACA P17612 2/20 0.31
PRKACG P22612 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2794876 0.85 KCNH2 (0.39) KCNH2CNR1CNR2OPRM1OPRL1
SCHEMBL2799216 0.85 KCNH2 (0.48) KCNH2CNR1CNR2OPRM1OPRL1
SCHEMBL2800993 0.80 NPY1R (0.39) KCNH2CNR1CNR2ALDH1A1HPGD
Hydrochloric Acid SCHEMBL2799106 0.80 KCNH2 (0.37) KCNH2CNR1CNR2ALDH1A1TP53
SCHEMBL2797625 0.78 KCNH2 (0.36) KCNH2CNR1CNR2OPRM1OPRD1
Hydrochloric Acid SCHEMBL2798696 0.78 KCNH2 (0.37) KCNH2CNR1CNR2OPRM1OPRD1
SCHEMBL2796649 0.77 KCNH2 (0.39) KCNH2CNR1CNR2
SCHEMBL2800252 0.77 KCNH2 (0.43) KCNH2CNR1CNR2
SCHEMBL2797739 0.77 KCNH2 (0.40) KCNH2CNR1CNR2ALDH1A1TP53
SCHEMBL2796334 0.77 MCHR1 (0.39) KCNH2CNR1CNR2OPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524738-B2 Quinolinones and quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2013-09-03 US disclosed
US-8329694-B2 Quinoxalinones as antibacterial composition TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-08-23 US disclosed
EP-2468743-A1 Nitrogen-containing bicyclic compounds useful as antibacterial agents Toyama Chemical Co., Ltd. (JP) 2012-06-27 EP disclosed
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2010-07-01 US disclosed
EP-1900732-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2008-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168418-A1 NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF ROS1, NOX1, ARG1 KCNH2 578/4885CNR1 673/4885CNR2 807/4885
US-20120214990-A1 QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION NQO2, ASNS, NDUFS1 KCNH2 525/4885CNR1 2005/4885CNR2 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.